Targeting Bcl3/NF-κB p50 Pathway for Neuroinflammation Attenuation and RGCs Protection in Retinal Ischemia/Reperfusion Injury
Investigative Ophthalmology & Visual Science · 2025-09-26 · 66 (12) · 63
DOI: 10.1167/iovs.66.12.63 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2025-09-26. Written by Meini Chen and 8 co-authors. Institution: Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Major MEDLINE topics: Reperfusion Injury, Retinal Ganglion Cells, NF-kappa B p50 Subunit, Retinal Diseases. Cited 4 times so far (Crossref); 74 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Retinal ischemia/reperfusion (IR) injury caused by pathologically high intraocular pressure (ph-IOP) induces excessive inflammation, contributing to retinal ganglion cell (RGC) death in glaucoma. Lowering IOP alone is insufficient, highlighting the need for neuroprotective strategies. Resveratrol (RSV) exhibits anti-inflammatory and neuroprotective effects, but its molecular mechanisms remain unclear. This study aims to evaluate RSV's neuroprotective role and underlying mechanisms in retinal IR injury.
Methods
Retinal morphology and RGC survival were assessed via immunofluorescence and hematoxylin and eosin (H&E) staining. Retinal function was evaluated using flash visual evoked potential (F-VEP) and flash electroretinogram (F-ERG). Inflammation and microglial activation were analyzed by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Pyroptosis and apoptosis were examined using Western blotting, TUNEL staining, and electron microscopy. RNA sequencing, qRT-PCR, and Western blotting identified molecular pathways.
Results
RSV significantly protected RGCs and preserved retinal function. It reduced inflammation by inhibiting microglial activation and redistribution. Electron microscopy confirmed its protective effects against apoptosis and pyroptosis. Most importantly, we identified the Bcl3/NF-κB p50 pathway as a key target of RSV. Using the Bcl3-NF-κB p50-specific inhibitor JS-6, we validated this pathway's role in reducing neuroinflammation, pyroptosis, and apoptosis.
Conclusions
This study provides insights into RSV's molecular mechanisms and identifies new therapeutic targets for glaucoma.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- National Clinical Key Specialty of Ophthalmology, Changsha, Hunan, People's Republic of China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, United States.
- Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Cite
APA
Chen, M., Zhang, X., Zeng, Z., Fan, C., Chen, S., Quan, C., Chen, J., You, M., & Xia, X. (2025). Targeting Bcl3/NF-κB p50 Pathway for Neuroinflammation Attenuation and RGCs Protection in Retinal Ischemia/Reperfusion Injury. Investigative Ophthalmology & Visual Science, 66(12), 63. https://doi.org/10.1167/iovs.66.12.63
Vancouver
Chen M, Zhang X, Zeng Z, Fan C, Chen S, Quan C, et al. Targeting Bcl3/NF-κB p50 Pathway for Neuroinflammation Attenuation and RGCs Protection in Retinal Ischemia/Reperfusion Injury. Investigative Ophthalmology & Visual Science. 2025;66(12):63. doi:10.1167/iovs.66.12.63
BibTeX
@article{Chen2025,
author = {Chen, Meini and Zhang, Xuan and Zeng, Zhou and Fan, Cong and Chen, Si and Quan, Chao and Chen, Jiachang and You, Mengling and Xia, Xiaobo},
title = {Targeting Bcl3/NF-κB p50 Pathway for Neuroinflammation Attenuation and RGCs Protection in Retinal Ischemia/Reperfusion Injury},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {12},
pages = {63},
doi = {10.1167/iovs.66.12.63}
}
EUVIMED